**TABLE 1 Baseline Demographic Variables in the DolPHIN-2 Intent to Treat Population**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variable** | **Statistic** | **Dolutegravir (N=125)** | **Efavirenz (N=125)** | **Total (N=250)** |
| Age (years) | Mean (SD) | 28·0 (5·3) | 27·4 (5·1) | 27·7 (5·2) |
| CD4 Count (cells per µL) | Median (IQR) | 464 (329– 664) | 414 (265 – 581) | 446 (296 – 633) |
| Log10 Viral Load | Median (IQR) | 4·4 (3·6 - 4·7) | 4.6 (3·9 - 4·8) | 4.4 (3·8 - 4·8) |
| Estimated gestation age (weeks) | Median (IQR) | 31 (29 -34) | 31 (29 -33) | 31 (29 -34) |
| Gravidity | Median (IQR) | 3 (2 – 4) | 3 (2 – 4) | 3 (2 – 4) |
| Previous live births  | Median (IQR) | 2 (1 – 3) | 1 (1-2) | 2 (1-3) |
| Primigravida | Number (%) | 16 (12·8%) | 14 (11·2%) | 30 (12·0%) |
| Previous stillbirths | Yes (%) | 2 (1·6%) | 2 (1·6%) | 4 (1·6%) |
| Use of herbal/ traditional medicine | Yes (%) | 42 (33·6%) | 45 (36·0%) | 87 (34·8%) |
| Use of supplements and vitamins | Yes (%) | 48 (38·4%) | 46 (36·8%) | 94 (37·6%) |
| Other co-medications | Yes (%) | 31 (24·8%) | 38 (30·4%) | 69 (27·6%) |
| Tobacco consumption in pregnancy | Yes (%) | 7 (5·6%) | 7 (5·7%) | 14 (5·6%) |
| Alcohol consumption in pregnancy | Yes (%) | 22 (17·6%) | 27 (21·6%) | 49 (19·6%) |
| History of psychiatric disorders | Yes (%) | 8 (6·5%) | 3 (2·4%) | 11 (4·4%) |
| Weight (kg) | Mean (SD) | 75·1 (16·1) | 71·8 (15·6) | 73·4 (16·0) |
| Height (cm) | Mean (SD) | 157·2 (7.8) | 158·0 (8·1) | 157·6 (7·9) |
| Site  | South Africa | 57(45·60) | 57(45·60) | 114(45·60) |
| Uganda | 68(54·40) | 68(54·40) | 136(54·40) |

**TABLE 2 DolPHIN-2 Efficacy Results by General Linear Model**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  |  | no/No (%) of patients with events) | Estimate of relative risk (95% CI),P value | Estimate of risk difference (95% CI),P value | P-value for interaction test |
|  |  | Dolutegravir | Efavirenz | Dolutegravir vs Efavirenz | Dolutegravir vs Efavirenz |  |
|  |  |  |  |  |  |  |
| **Outcome** |  |  |  |  |  |  |
| **Maternal HIV viral load <50 copies**  | **Primary analysis\*** | 89/120 (74·2) | 50/117 (42·7) | 1.64 (1·31,2·06), <0·0001 | 29·78 (18·18,41·37), <0·0001 |  |
| **per mL at delivery(primary outcome)** | **Covariate-adjusted analysis\*\***  |  |  | 1.65 (1.31,2.06), <0·0001 | 30·48 (18·97,41·98), <0·0001 |  |
| Maternal HIV viral load <1000 copies | Primary analysis\* | 112/120 (93·3) | 96/117 (82·1) | 1·12 (1·00,1·25), 0·042 | 9·89 (0·94,18·84), 0·030 |  |
| per mL at delivery | Covariate-adjusted analysis\*\*  |  |  | 1·10 (0·99,1·23), 0·089 | 10·36 (0·26,20·47), 0·044 |  |
| **By Subgroup** | Subgroup analysis\* |  |  |  |  |  |
| Age | Age<28 | 39/54 (72·2) | 24/59 (40·7) | 1·71 (1·20,2·43), 0·003 | 31·60 (14·56,48·64), 0·0003 | 0·867 |
|  | Age≥28 | 50/66 (75·8) | 26/58 (44·8) | 1·61 (1·20,2·16), 0·001 | 26·66 (10·49,42·83), 0·001 |  |
| Country | South Africa | 43/56 (76·8) | 25/55 (45·5) | 1·64 (1·19,2·25), 0·002 | 30·01 (12·97,47·04), 0·0006 | 0·931 |
|  | Uganda | 46/64 (71·9) | 25/62 (40·3) | 1·55 (1·16,2·09), 0·004 | 28·45 (11·18,45·71), 0·001 |  |
| Viral load at baseline  | Viral load<100,000 copies per mL | 81/103 (78·6) | 47/95 (49·5) | 1·59 (1·27,1·99), <0·0001 | 29·13 (16·34,41·91), <0·0001 | 0·274 |
|  | Viral load≥100,000 copies per mL | 8/17 (47·1) | 3/22 (13·6) | 3·41 (1·04,11·14), 0·042 | 32·93 (5·14,60·72), 0·020 |  |
| CD4 at baseline | CD4≥200 | 81/107 (75·7) | 46/99 (46·5) | 1·61 (1·27,2·02), <0·0001 | 28·95 (16·48,41·42), <0·0001 | 0·600 |
|  | CD4<200 | 8/13 (61·5) | 4/18 (22·2) | 2·30 (0·86,6·15), 0·097 | 35·39 (3·35,67·43), 0·030 |  |
| Gestational age at  | Gestational age<36 | 72/97 (74·2) | 46/103 (44·7) | 1·64 (1·29,2·07), <0·0001 | 29·80 (17·34,42·25), <0·0001 | 0·522 |
| initiation of HIV therapy | Gestational age≥36 | 17/23 (73·9) | 4/14 (28·6) | 1·35 (0·79,2·30), 0·277 | 27·90 (-9·55,65·35), 0·144 |  |

\* The generalized linear model has the treatment as a study variable, viral load (≥ or <100,000 copies) and CD4(≥ or <200 cells per µL) as covariables

\*\* The generalized linear model has the treatment as a study variable, viral load (≥ or <100,000 copies), CD4(≥ or <200 cells per µL), age (< or ≥ median in years), country (South African or Uganda), and gestational age at enrolment (< or ≥ 36 weeks) as covariables

**TABLE 3 Serious adverse events, and pre-term deliveries in mothers and infants**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Dolutegravir** | **Efavirenz** | **Total** |
| **Maternal SAEs** | **N = 137 (%)** | **N = 131 (%)** | **N = 268 (%)** |
| Mothers with ≥1 SAE1 | 30 (21·9)2 | 14 (10·7)2 | 44 (16·4) |
| Mothers with ≥1 drug-related SAE | 1 (0·7) | 0 | 1 (0·4) |
| Mothers with ≥1 IRIS-related SAE | 1 (0·7) | 0 | 1 (0·4) |
| **SYSTEM ORGAN CLASS** |  |  |  |
| Blood and lymphatic system disorders | 2 (1·5) | 0 | 2 (0·7) |
| Gastrointestinal disorders | 1 (0·7) | 0 | 1 (0·4) |
| Infections and infestations | 5 (3·6) | 2 (1·5)  | 7 (2·6) |
| Pregnancy, puerperium and perinatal conditions excl. stillbirths | 18 (13·1) | 10 (7·6) | 28 (10·4) |
| Renal and urinary disorders | 3 (2·2) | 0 | 3 (1·1) |
| Social circumstances | 1 (0·7) | 0  | 1 (0·4) |
| Vascular disorders | 0 | 1 (0·8) | 1 (0·4) |
| Deliveries with evaluable gestational age | **N = 124** | **N = 120** | **N = 244** |
| Gestation3 at delivery (median; IQR) | 39 (37·2, 40·7) | 39 (37·3, 40·0) | 39 (37·3, 40·3) |
| Late pre-term (<37 weeks) | 21 (16·9) | 19 (15·8) | 40 (16·4) |
| Premature (< 34 weeks) | 3 (2·4) | 5 (4·2) | 8 (3·3) |
| Stillbirth | 3 (2·2) | 1 (0·8) | 4 (1·5) |
| **Infant SAEs (242 live births)** | **N = 123 (%)** | **N = 119 (%)** | **N = 242 (%)** |
| Birth weight (g; median; IQR) | 3180 (2800, 3440) (N = 109) | 3115(2860, 3420) (N = 118) | 3160 (2840, 3440) (N = 227) |
| Infants with ≥1 SAE | 61 (49·6) | 56(47·1) | 117 (48·3) |
| Infant deaths | 4 (3·3) | 2 (1·7) | 6 (2·5) |
| **SYSTEM ORGAN CLASS** |  |  |  |
| Congenital, familial and genetic disorders | 67 (54·5) | 71 (59·7) | 138 (57·0) |
| Ear and labyrinth disorders | 1 (0·8) | 0 | 1 (0·4) |
| Hepatobiliary disorders | 1 (0·8) | 0 | 1 (0·4) |
| Infections and infestations | 8 (6·5) | 6 (5·0) | 14 (5·8) |
| Injury, poisoning and procedural complications | 1 (0·8) | 0 | 1 (0·4) |
| Nervous system disorders | 1 (0·8) | 1 (0·8) | 2 (0·8) |
| Pregnancy, puerperium and perinatal conditions | 4 (3·3) | 7 (5·9) | 11 (4·5) |
| Respiratory, thoracic and mediastinal disorders | 8 (6·5) | 4 (3·4) | 12 (5·0) |

1 Including stillbirths.

2 P = 0·013, Chi-squared test

3 Gestation at delivery based on best estimate using recall of last menstrual period, fundal height and ultrasound dating, modified post-partum by the Ballard score.